PFKFB3 and neoplasm: Both genetic ablation and the pharmacological inhibition [44] of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-3 (PFKFB3), a key enzyme in glycolysis regulation, inhibit blood vessel formation in tumor xenografts (Table 1).